A. Age younger than 60 years and no history of thrombosis B. Age younger than 65 years with a history of thrombosis C. Age younger than 60 years and no constitutional symptoms upon diagnosis D. Age younger than 60 years or no history of thrombosis E. Unsure

A. In a male patient with low-risk disease in which a hematocrit of less than 45% is being maintained with aspirin and phlebotomy B. In a high-risk patient who continues to have palpable splenomegaly, pruritus symptoms, and a decreased absolute neutrophil count after 6 months of treatment with hydroxyurea C. In a patient who is receiving interferon alpha who has achieved a molecular remission of the JAK2 V617F mutation D. In a patient whose PV disease has transformed into acute myeloid leukemia E. Unsure

A. Counsel the patient to report any leg swelling or cramping to their health care provider as this could be a sign of deep vein thrombosis B. Recommend that the patient with PV who is being treated with ruxolitinib receive both a zoster vaccine and pneumococcal vaccine C. Counsel the patient to avoid hot showers or baths because this can exacerbate pruritis D. Recommend that the patient with PV who is being treated with ruxolitinib be prescribed voriconazole as an antifungal because of the risk of infection with ruxolitinib E. Unsure